Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/12/2025

Weight Management with Aripiprazole and Atomoxetine

Introduction to Weight Management

  • Aripiprazole is considered among the lower-risk antipsychotics for weight gain compared to olanzapine, clozapine, quetiapine, and risperidone, but it is not weight-neutral despite common misconceptions, according to the American Gastroenterological Association 1

Active Weight Management Interventions

  • Initiate lifestyle interventions immediately at treatment start, not after weight gain occurs—this is critical for prevention, as recommended by the American Gastroenterological Association 1
  • If weight gain ≥7% occurs despite interventions, consider adding pharmacotherapy for weight management or switching antipsychotics, as suggested by the American Medical Association 1 and the Journal of the American Medical Association 2

Lifestyle Modification Specifics

  • Implement dietary counseling focused on reduced portion sizes and increased fiber intake at treatment initiation—this is particularly important for managing GI side effects of weight-loss medications if later needed, according to the Journal of the American Medical Association 2
  • Prescribe structured physical activity with specific targets (e.g., 150 minutes of moderate-intensity exercise weekly), as recommended by the Journal of the American Medical Association 2

Pharmacotherapy Options for Weight Management

  • GLP-1 receptor agonists (semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily) are first-line pharmacotherapy options, producing 14.9% and 8% weight loss respectively, as reported by the Journal of the American Medical Association 2
  • Metformin (up to 2500 mg daily) can be considered, particularly if prediabetes or insulin resistance develops, producing approximately 3.5% weight loss, according to the Journal of the American Medical Association 2
  • Topiramate (as monotherapy or in combination with phentermine) produces weight loss but requires careful consideration given its anticonvulsant properties—start at low doses and titrate slowly, as recommended by the American Gastroenterological Association 1 and the Journal of the American Medical Association 2

Medication Switching Considerations

  • If weight gain is severe (≥10% of baseline) and refractory to interventions, consider switching from aripiprazole to ziprasidone or lurasidone, which are the most weight-neutral antipsychotics, as suggested by the American Gastroenterological Association 1
  • Studies demonstrate that patients lose weight when switched from olanzapine to ziprasidone, suggesting switching strategies can be effective, according to the American Gastroenterological Association 1